T

[Adam @ABrokenBattery]

Today marks 25 years since 9/11. 8 months after the attack, psychiatrist Simon Wessely argued that illness reported around Ground Zero was being wrongly attributed to environmental toxins, suggesting “World Trade Centre Syndrome” was driven by social and psychological factors.

[T @TLDnoR]

@ThePEIMatrix @JackHadfield14 So a bubble of folks freaked out on Twitter but now every patient is crazy? That same conference was run by a patient btw. The same guy that was the victim of the harassment. You need some nuance or you’re no better than them tbh.

[Carole Bruce @CaroleBruce17]

This #ME symposium beginning on Friday has an impressive line up of speakers. It will be recorded for us. Let’s let the researchers proceed in peace without point scoring remarks that need defending. We all want to get well and needless division detracts from that possibility.

[Christoph Ströck @cstroeckw]

Schwer in Worte zu fassen, was für ein absoluter Wahnsinn im medizinischen Bereich leider zum Alltag gehört. Für ME/CFS-Betroffene ist das nicht die Ausnahme, sondern die Regel. In welcher Welt ist soetwas nicht rechtlich relevant? Absolute shitshow!

[T @TLDnoR]

@P1231032850 @grok It’s in the abstract book from the ISLC conference ✨

[T @TLDnoR]

„Inefficient energy consumption is a hallmark of post-viral syndromes during cardiopulmonary exercise“

“Conclusion

LC, ME/CFS and GWI have inefficient energy production at rest and exertion. This finding might explain chronic fatigue and exercise intolerance in these patients.”

[T @TLDnoR]

@ThePEIMatrix @JackHadfield14 What a load of rubbish. What world are you living in? We’re all desperately hoping for Pharma funds.

[T @TLDnoR]

@JackHadfield14 Scheibenbogen managed to get Sanofi to sponsor a nicely set up CD-38 antibody trial (same class as Daratumumab). So there is some hope. I’d really love for that trial to succeed and hopefully snowball into more.

[Hiroshi Yasuda (保田浩志) @Yash25571056]

From a study of 154 participants,
"Long COVID participants performed significantly worse on both olfactory and gustatory function tests compared to No COVID controls.
Subjective assessment of olfactory and gustatory function only weakly correlated with objective test performance in the Long COVID group.
Time since COVID-19 infection did not correlate with dysfunction severity in either Long COVID or Ex COVID group..
[In conclusion,] Olfactory and gustatory dysfunction was more common in the Long COVID cohort than in controls..
self-perceived sensory impairment only weakly correlated with objective measures.."

We cannot sense the loss of a sense because of the loss of the sense.

'Olfactory and gustatory perception in adults with long COVID'
https://t.co/szGi7zoO3O

[Miguel Ángel Abellanas @maabellanas]

This started as a question I couldn't let go of: if monocyte-derived macrophages help the Alzheimer's brain, why does the body stop sending them?

Several years, a lot of femurs and one very long review process later, we have an answer. Out today in @NatureNeuro 🧵

[T @TLDnoR]

@manruipa Helps me quite a bit and mainly in the rebalancing parasympathetic tone department though it’s also
slightly beneficial for my pots. Raised my PEM threshold a little as well.

[tern @1goodtern]

THAT'S BECAUSE WE'RE NOT POST PANDEMIC.

[T @TLDnoR]

@32Sfc46582 @C_Scheibenbogen Switching to an ad hominem attack and claiming I am some sort of blinded follower really isn’t productive either. I don’t subscribe to that kind of culture of outrage.

[Solve ME/CFS Initiative @PlzSolveCFS]

Starts today at 3 pm PT / 6 pm ET! Join our webinar with Dr. Jay H. Chung (NIH), who will discuss his Solve ME/CFS Catalyst Award-winning study of a potential safe and accessible treatment for #MECFS.
https://t.co/juY29GEfu7

[Tom Kindlon @TomKindlon]

10 years today, after a David vs Goliath FOI legal battle that damaged Alem Mathees, White et al were forced to release data from PACETrial that cost UK taxpayers £5M showing graded exercise therapy & CBT didn’t lead to an increased recovery rate for CFS.

Please remind the world

[T @TLDnoR]

@32Sfc46582 @C_Scheibenbogen Anyone can miss something especially if it has nothing to do with their specialty imo. We’re all just human, even researchers.

[T @TLDnoR]

@C_Scheibenbogen Zum Nachlesen:

[T @TLDnoR]

@C_Scheibenbogen Chris Ponting (Decode ME Autor) war der Studie sehr kritisch gegenüber. Scheinbar war der Signifikanz Cutoff deutlich schwächer als bei genetischen Studien üblich. Zudem ist vieles an deren Prozess hinter deren Trademark verborgen. Sieht für mich eher nach nichts aus.

[@longcovidtheanswers @longcovidanswer]

What if some of #LongCOVID’s answers are hiding in our tissues?

Prof @MichaelPelusoMD explains why he's studying tissue samples to uncover signals that blood tests may miss.
#longhauler #mecfs #longcovidtheanswers #longcovidresearch

[Massimo @Rainmaker1973]

A single dose of a new cancer drug made a brain tumor almost disappear – in just five days.

Doctors at Massachusetts General Hospital reported “dramatic and rapid” tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma, one of the most aggressive brain cancers known.

The therapy, called CARv3-TEAM-E, was developed to overcome a major hurdle in treating solid tumors: their ability to hide from the immune system.

The personalized treatment reprograms a patient’s immune cells to attack the tumor, and in one extraordinary case, nearly eliminated the cancer within just five days. This novel therapy is designed to target multiple features of the tumor at once, a strategy that may help overcome the common challenge of treatment resistance in solid tumors like glioblastoma.

Although the tumors eventually returned, the early outcomes were described as unprecedented. One patient saw a 60% reduction in tumor size that lasted for half a year—an impressive result in a cancer known for its aggressiveness.

The trial’s success marks a major step forward for immunotherapy in brain cancer and raises new hopes for long-term control or even a cure. Researchers are now working to refine the treatment and extend its effects, with the ultimate goal of turning a once-terminal diagnosis into a survivable condition.